WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013147212) NOVEL ANTI-SIGLEC15 ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/147212    International Application No.:    PCT/JP2013/059653
Publication Date: 03.10.2013 International Filing Date: 29.03.2013
IPC:
C12N 15/09 (2006.01), A61K 39/395 (2006.01), A61K 45/00 (2006.01), A61P 19/02 (2006.01), A61P 19/10 (2006.01), A61P 29/00 (2006.01), A61P 35/00 (2006.01), A61P 35/04 (2006.01), C07K 16/18 (2006.01), C07K 16/46 (2006.01), C12N 1/15 (2006.01), C12N 1/19 (2006.01), C12N 1/21 (2006.01), C12N 5/10 (2006.01), C12P 21/08 (2006.01)
Applicants: DAIICHI SANKYO COMPANY,LIMITED [JP/JP]; 3-5-1,Nihonbashi Honcho,Chuo-ku, Tokyo 1038426 (JP)
Inventors: HIRUMA, Yoshiharu; (JP).
HASEGAWA, Jun; (JP)
Agent: ISHIBASHI Koki; c/o DAIICHI SANKYO COMPANY, LIMITED, 1-2-58, Hiromachi,Shinagawa-ku Tokyo 1400005 (JP)
Priority Data:
2012-078841 30.03.2012 JP
Title (EN) NOVEL ANTI-SIGLEC15 ANTIBODY
(FR) NOUVEL ANTICORPS ANTI-SIGLEC15
(JA) 新規抗Siglec-15抗体
Abstract: front page image
(EN)To provide an abnormal-bone-metabolism treatment and/or a prophylactic pharmaceutical composition targeting a protein coded for by a gene that is strongly expressed in osteoclasts. The provision, etc., of a pharmaceutical composition containing an antibody that specifically recognizes human SIGLEC15 and exhibits the effect of inhibiting the formation of osteoclasts.
(FR)Cette invention concerne le traitement d'un métabolisme osseux anormal et/ou une composition pharmaceutique à visée prophylactique ciblant une protéine codée par un gène qui est fortement exprimé dans les ostéoclastes. L'utilisation, etc., d'une composition pharmaceutique contenant un anticorps qui reconnaît spécifiquement le SIGLEC15 humain et ayant pour effet d'inhiber la formation des ostéoclastes est décrite.
(JA) 破骨細胞で強く発現する遺伝子にコードされる蛋白質を標的とした骨代謝異常治療及び/又は予防用医薬組成物を提供すること。 ヒトSiglec-15を特異的に認識し、破骨細胞の形成を抑制する活性を有する抗体を含む医薬組成物の提供等。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)